Pay in 4 interest-free payments of $6.58 Learn more
Ships within 48 hours · Estimated delivery Oct 25 - Oct 30
Current Status of the Litigation The Ozempic litigation is currently moving forward in a Multidistrict Litigation (MDL 3094) in the Eastern District of Pennsylvania
Vilsbll T, Krarup T, Madsbad S, Holst JJ
In February 2025, Gan & Lee Pharmaceuticals (hereafter referred to as "Gan & Lee," stock code: 603087.SH) unveiled that the first participant was successfully dosed in a large-scale Phase 3 clinical trial (OPTIMUM-2) of Bofanglutide, a bi-weekly glucagon-like peptide-1 receptor agonist (GLP-1RA) independently, in Chinese participant with type 2 diabetes mellitus (T2DM)
Da eine berdosierung nicht empfehlenswert ist, sollten die Produkthinweise zur Einnahme stets beachtet werden
Dietary advice and review may also be needed
